- Oops!Something went wrong.Please try again later.
Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.
Heat Biologics is a U.S.-based immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates.
Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells that secrete tumor-associated antigens together with an immune response stimulator called gp96.
Heat Biologics shares were trading up 2.88% at 77 cents on Monday. The stock has a 52-week high of $1.26 and a 52-week low of 20 cents.
Heat Biologics Shares React Amid Circulation Of PatentScope Doc
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.